Creative Medical Technology Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Tim Warbington

İcra Kurulu Başkanı

US$732.7k

Toplam tazminat

CEO maaş yüzdesi	46.36%
CEO görev süresi	10.4yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	5.5yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • May 12

Creative Medical Technology Holdings: Initiating Coverage With A Sell Rating

Summary Initiating coverage on Creative Medical Technology Holdings with a Sell rating due to early-stage pipeline and significant downside risks outweighing potential upside. The company’s pipeline includes AlloStem for diabetes, AlloStemSpine for back pain, and OvaStem for infertility, all in early development with high uncertainty. Financially, Creative Medical has limited cash reserves, high cash burn, and will likely need dilutive financing, posing significant risks to current shareholders. Competing therapies from larger companies in diabetes and back pain markets could overshadow Creative Medical’s offerings, making commercial success uncertain. Read the full article on Seeking Alpha

CEO Tazminat Analizi

Tim Warbington'un ücretlendirmesi Creative Medical Technology Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	n/a	n/a	-US$6m
Dec 31 2025	US$733k	US$340k	-US$6m
Sep 30 2025	n/a	n/a	-US$6m
Jun 30 2025	n/a	n/a	-US$6m
Mar 31 2025	n/a	n/a	-US$6m
Dec 31 2024	US$587k	US$339k	-US$5m
Sep 30 2024	n/a	n/a	-US$5m
Jun 30 2024	n/a	n/a	-US$6m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$523k	US$330k	-US$5m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$469k	US$330k	-US$10m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	n/a	n/a	-US$9m
Mar 31 2022	n/a	n/a	-US$10m
Dec 31 2021	US$99k	US$99k	US$19m

Tazminat ve Piyasa: Tim 'ın toplam tazminatı ($USD 732.72K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 659.85K ).

Tazminat ve Kazançlar: Tim şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Tim Warbington (64 yo)

10.4yrs

Görev süresi

US$732,720

Tazminat

Mr. Timothy Warbington, also known as Tim, is Co-Founder of Creative Medical Technology Holdings, Inc. and serves as its Chief Executive Officer since February 2016 and serves as its President since May 18...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Timothy Warbington	Co-Founder	10.4yrs	US$732.72k	0.33% $ 14.8k
Donald Dickerson	Senior VP	10.4yrs	US$560.00k	0.00046% $ 20.6
Susan Snow	Independent Director	4.6yrs	US$120.00k	Veri yok
Timothy Henry	Member of Scientific Advisory Board	8.1yrs	Veri yok	Veri yok
Boris Reznik	Member of Scientific Advisory Board	5.5yrs	Veri yok	Veri yok
Camillo Ricordi	Member of Scientific Advisory Board	5.2yrs	Veri yok	Veri yok
Santosh Kesari	Member of Scientific Advisory Board	9.6yrs	Veri yok	Veri yok
Michael Finger	Independent Director	4.6yrs	US$80.00k	0.0095% $ 424.9
Bruce Urdang	Independent Director	4.6yrs	US$100.00k	Veri yok

5.5yrs

Ortalama Görev Süresi

67.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CELZ 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/07/05 06:29
Gün Sonu Hisse Fiyatı	2026/07/02 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Creative Medical Technology Holdings, Inc. 1 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jonathan Aschoff	Roth Capital Partners

Creative Medical Technology Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 18, 2025

Insufficient new directors

Creative Medical Technology Holdings, Inc., Annual General Meeting, Jul 19, 2024

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 20, 2023

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 19, 2022

Recent updates

Creative Medical Technology Advances Chronic Pain and Osteoarthritis Programs in FDA-Backed Trials

Creative Medical Technology Holdings, Inc. has withdrawn its Follow-on Equity Offering.

Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering.

New minor risk - Share price stability

Creative Medical Technology Holdings Expands Adapt Trial And Advances Toward Phase 3 Planning For Olastrocel In Chronic Lower Back Pain

Creative Medical Technology Holdings Advances Project Phoenix into Nationwide Ai Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

No longer forecast to breakeven

First quarter 2026 earnings released: US$0.38 loss per share (vs US$0.83 loss in 1Q 2025)

Creative Medical Technology Holdings, Inc. Reports Breakthrough Response Rate in Ultrasome Knee Osteoarthritis Program and Expands CELZ-201 Platform Into Scalable Cell-Free Regenerative Therapies

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from Adapt Trial and Celz-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain

Forecast to breakeven in 2028

Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared Adapt Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point

Creative Medical Technology Holdings Announces World Health Organization Approval of "Olastrocel" as Inn for Lead Allogeneic Cell Therapy Celz-201

No longer forecast to breakeven

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 18, 2025

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain

Second quarter 2025 earnings released: US$0.48 loss per share (vs US$1.11 loss in 2Q 2024)

New major risk - Market cap size

Creative Medical Technology Holdings: Initiating Coverage With A Sell Rating

New major risk - Shareholder dilution

Creative Medical Technology Holdings Provides Nasdaq Compliance Update

Forecast breakeven date pushed back to 2027

New major risk - Share price stability

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

Creative Medical Technology Reports Positive One-Year Results for Allostem™? Type 2 Diabetes Program

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Insufficient new directors

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

New minor risk - Shareholder dilution

Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million.

New minor risk - Share price stability

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Creative Medical Technology Holdings, Inc., Annual General Meeting, Jul 19, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access

Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem

New major risk - Financial position

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 20, 2023

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain

Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem™ (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain

Creative Medical Technology Holdings Regains Compliance with Nasdaq Listing Requirements

Creative Medical Technology Holdings, Inc. (NasdaqCM:CELZ) announces an Equity Buyback for $2 million worth of its shares.

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy Platform

Creative Medical Technology Holdings, Inc. Announces Next Milestone Achievements in ImmCelz Platform Development

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Creative Medical Technology Holdings, Inc. Announces Positive Three-Year Follow-Up Data for the Company's Stemspine Pilot Study

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc. Announces Fda Clearance of Investigational New Drug (Ind) Application for Allostem(Tm), A Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 19, 2022

Creative Medical Technology Holdings, Inc. Develops AlloStem Clinical Cell Line

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Creative Medical Technology Holdings Receives Non-Compliance Notice from Nasdaq

Creative Medical Technology Holdings, Inc. announced that it has received $17.000001 million in funding

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc. Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

High number of new and inexperienced directors

Creative Medical Technology Holdings Deleted from Other OTC

Less than half of directors are independent

Creative Medical Technology Holdings, Inc. announced that it has received $3.78775 million in funding

Creative Medical Technology Holdings, Inc. announced that it expects to receive $3.788 million in funding

Creative Medical Technology Holdings Identifies Synergy Between Immcelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease

FDA Responds to Creative Medical Technology Holdings, Inc. Regarding its ImmCelz® IND for Stroke Treatment